This is the first case report of a Mycobacterium thermoresistibile infection following augmentation mammaplasty and is the fourth human case report ofM. thermoresistibile infection. Antimicrobial susceptibility results determined by a modified proportion method using a 3-day incubation were the same as those determined by the standard 3-week assay.
Mycobacterium thermoresistibile was first isolated from soil in 1966 by Tsukamura (9) , who described it as a rapidly growing mycobacterium capable of growth at 52°C. In 1981, M. thermoresistibile was first recognized as a human pathogen when isolated from a case of pneumonia (13) . Subsequently, M. thennoresistibile was reported as the causative agent of a pulmonary granuloma (6) and a cutaneous infection following a cardiac transplantation (7) . There has been an additional report of an infection in a cat with cutaneous lesions and local lymph node involvement (14) . This is the fourth human case report of an infection caused by M. thernoresistibile.
Case report. The patient is a 41-year-old healthy Caucasian female who underwent bilateral subpectoral augmentation in August 1988. She had no prior history of mycobacterial disease. She did well initially but developed a seroma in the right breast 3 weeks after surgery. Aerobic and anaerobic cultures of the aspirated fluid were negative. Approximately 2 1/2 months after surgery, she developed a contracture in her right breast, and the implant was removed. Aerobic and anaerobic cultures were again negative. Three weeks after the implant was removed, Staphylococcus epidermidis was isolated from drainage at the incision. The patient was treated with antibiotics on the basis of the results of the susceptibility test, and the clinical symptoms were resolved.
In August 1989, the patient underwent a second augmentation mammaplasty of her right breast. Three months postoperatively, she again developed a contracture in her right breast, and the implant was removed. It was found to be coated with a thick yellow fluid which was negative on aerobic, anaerobic, and fungal culture. A heavy serous drainage from the incision site continued for 9 months. During this period, the patient remained afebrile. In August 1990, an abscess that formed above the incision was drained. Routine cultures were negative, but a mycobacterial culture was not done.
In September 1990, an atypical mycobacterium was recovered from sinus drainage from another breast abscess by a local hospital laboratory. The culture was referred to the Orange County Public Health Laboratory and subsequently identified as M. thermoresistibile. Therapy consisting of rifampin (600 mg daily) and ethambutol (1,600 mg daily) was begun. Because of potential toxicity, the dosage of ethambutol was reduced to 1,000 mg daily after 4 months.
Four months after initiation of therapy, a newly formed breast abscess was aspirated, and M. thermoresistibile was again isolated. Nine months after therapy began, the patient was clinically improved, with one small abscess remaining. Sixteen months after therapy began, the patient was fully recovered.
Microbiological tests. (Table 1) . However, one previous isolate was reported to be nitrate negative (13) and one was reported as tellurite positive (7). A major difference is that all of the reported human isolates have been Tween-80 hydrolysis positive, while the 14 soil isolates tested by Tsukamura were all negative (10). Whether this is due to variations in testing procedures is not known. Resistance to isoniazid (INH) andp-aminosalicyclic acid was also reported by others who performed susceptibility tests (6, 7, 13) . There was one report of resistance to low levels of streptomycin (2 ,ug/ml) (13), which is in contrast to our result.
While this is the first report of an M. thernoresistibile infection after an augmentation mammaplasty, postmamma- (1, 2, 11) . Clinically, this case has features reported to be common to those caused by M. fortuitum and M. chelonae; the incubation time is close to a reported mean of 32 days, there was no history of fever, the establishment of an etiologic agent was delayed,. and when the implant was removed, serosanguineous or purulent material was present (1) .
The specific source of M. thermoresistibile in this infection is unknown. M. thennoresistibile has been isolated from soil samples (9) . However, it is not known whether this organism is as ubiquitous as M. fortuitum and M. chelonae, which are common environmental isolates (5) that have also been isolated from hospital water sources (3, 12) . Thus, this type of surgical infection may represent the result of a low-level environmental contamination. The possibility of a common source of contaminated implants or other surgical supplies was addressed by an epidemiologic study of postmammaplasty mycobacterial infections. The results of the study indicated no evidence for a common contaminated product (1).
The incidence of M. thernoresistibile infections appears to be low, but problems with the misidentification of this organism as M. flavescens or M. gordonae due to similar pigmentation may contribute to the low frequency of reported isolation. With increasing evidence that this organism can cause serious infections, efforts should be made by laboratories to properly identify M. thermoresistibile. Testing all suspected scotochromogens for rapid growth by incubating a subculture on a Ldwenstein-Jensen slant at 52°C for 4 days is a method which we have incorporated to easily screen for M. thermoresistibile. M. phlei, another mycobacterium which grows at 52°C, is also a rapid grower at 25°C and differs from M. thermoresistibile in biochemical reactions.
Modification of the proportion susceptibility test method was successful in our laboratory and reduced the time for results from 3 weeks to 72 h. Modification of the incubation temperature of the disk elution test also allowed us to determine resistance to several drugs. Since these are unstandardized techniques, as are all susceptibility tests for rapidly growing mycobacteria, the results must be utilized with caution, taking into account previously published susceptibility patterns and patients' responses to treatment. Further studies are necessary to confirm the accuracy of these modified techniques for other isolates of M. thernoresistibile.
